The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...

Rinvoq (upadacitinib) is a prescription drug used to treat certain autoimmune conditions. This drug can interact with some medications, vaccines, and supplements. For example, Rinvoq can interact ...

Rinvoq (upadacitinib) and cost Medically reviewed by Victor Nguyen, PharmD, MBA — By Alex Brewer, PharmD, MBA — Updated on February 16, 2024 Price and savings FAQ ...

Rinvoq (upadacitinib) is a brand-name drug prescribed for certain autoimmune conditions. Rinvoq has interactions with some drugs, supplements, and vaccines. Examples include certain antibiotics ...

Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has ...

The JAK1/2 inhibitor has been cleared for adults who are severely affected with the condition at a dose of 2mg once-daily ... and AbbVie's Rinvoq (upadacitinib). Olumiant is also approved to ...

AbbVie (ABBV) reported better-than-expected fourth-quarter results on Friday amid robust sales of Skyrizi and Rinvoq, ...

AbbVie said today it has submitted applications for a new indication for its immunology drug Rinvoq to the U.S. Food & Drug Administration and European Medicines Agency to treat adult patients ...

AbbVie Inc. ABBV announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for its JAK inhibitor, Rinvoq (upadacitinib), for a ...